💉 One Flu Shot to Rule Them All Finally Enters Human Trials

What if you could get one flu shot and actually not get the flu? Revolutionary concept, we know. This week, a 13-year vaccine odyssey finally reached human arms, the FDA decided pond scum belongs in everything, and researchers taught a blob of neurons to solve engineering problems. Meanwhile, drug testing got a tiny British upgrade, and someone in Zurich printed a functional ear because apparently we're living in the future now. Let's get into

NEWS

Every year, the flu vaccine is basically an educated guess. Scientists pick which strains they think will dominate, manufacture millions of doses, and then we all cross our fingers. When they guess wrong (which happens often), effectiveness can drop to as low as 10%. This is not ideal.

Centivax thinks they've cracked it. The South San Francisco company just dosed the first participants in a Phase 1 trial of Centi-Flu 01, a universal flu vaccine designed to work against basically all influenza strains (they're testing against more than 20, including H5N1 pandemic strains). The trick? Instead of targeting the constantly-mutating parts of the virus that make annual reformulation necessary, their vaccine directs immunity toward conserved regions that are less prone to mutate without killing the virus itself.

CEO Jacob Glanville has been working on this for 13 years (you might recognize him from Netflix's Pandemic documentary). His CMO, Jerry Sadoff, previously helped develop 14 approved vaccines, including Gardasil and the J&J COVID shot. The trial is running in Australia with initial data expected this year.

The global flu vaccine market exceeds $7 billion annually. If this works, a lot of annual guesswork becomes obsolete. No pressure.

NEWS

Remember when "natural blue food coloring" was basically an oxymoron? The FDA just fixed that. A final rule published February 6 expands spirulina extract from a specific list of permitted foods to general authorization for human foods. Effective March 23, your blue-colored snacks, baked goods, and pretty much anything else can now get their hue from pond scum instead of petroleum.

The pigment responsible is phycocyanin, extracted from Arthrospira platensis (spirulina), and it's a natural alternative for synthetic FD&C Blue No. 1. GNT USA, which has been pushing spirulina approvals since 2013, petitioned for the expansion. They make EXBERRY colors from fruits, vegetables, and plants, because of course they do.

This was part of a broader FDA package that also approved beetroot red for general use and introduced new "no artificial colors" labeling flexibility. The agency's stated goal: eliminate petroleum-based synthetic dyes by the end of 2027. Major manufacturers, including Kraft Heinz, General Mills, and PepsiCo, have pledged to phase them out.

The rule also tightened heavy metal limits considerably (lead dropped from 2 ppm to 0.2 ppm) and added cadmium limits for the first time. Still excluded: infant formula and USDA-regulated meat products. Your hot dogs remain petroleum-adjacent for now.

RESEARCH

Researchers at UC Santa Cruz grew mouse brain organoids, hooked them up to electrodes, and taught them to solve the cart-pole problem (that classic robotics test where you balance an inverted pendulum, like keeping a ruler upright on your palm). The results, published in Cell Reports, genuinely tickle our brains.

Here's what happened: organoids receiving targeted reinforcement learning feedback achieved 46% proficiency at the task. Organoids with no feedback? 2.3%. Random feedback? 4.5%. The blobs of neurons (each containing several million cells, and smaller than a peppercorn) were genuinely learning to solve an engineering problem through electrical stimulation.

Lead author Ash Robbins and senior authors David Haussler and Mircea Teodorescu call this the "first rigorous academic demonstration" of goal-directed learning in lab-grown brain tissue. It follows on the 2022 DishBrain experiment, where neurons learned to play Pong, but with more rigorous controls and 3D organoids instead of 2D cell layers.

The catch? After 45-minute rest periods, performance dropped back to baseline. The organoids forgot everything. Turns out memory requires brain infrastructure these tissue blobs don't have.

Haussler noted that using human brain organoids for computation "would bring up serious ethical issues". For now, they're sticking with mouse cells. Probably wise.

RESEARCH

Quick clarification on this one: the research comes from Texas A&M, but the technology is British. The PhysioMimix LC12, made by Cambridge-based CN Bio, is a liver-on-a-chip device that researchers just validated for catching species-specific drug toxicity.

The study, published in ACS Pharmacology & Translational Science, tested primary hepatocytes from humans, monkeys, rats, and dogs against drugs with known species-specific toxicity profiles. The chip more accurately reflected known toxicities than conventional 96-well plates, with cells remaining viable for up to 14 days (conventional cultures deteriorate much faster).

Why this matters: drug-induced liver injury is one of the most common reasons drugs fail in late-stage development. Catching it earlier, with better human-relevant models, could save billions in failed trials. Lead author Chander Negi acknowledged the system is more expensive than conventional methods, but "the improved accuracy and human relevance may justify this investment by reducing late-stage drug failures."

CN Bio's technology has been accepted into the FDA's ISTAND program as one of the participants and has a co-publication with the FDA itself. Senior author Ivan Rusyn noted that including immune systems and testing cells from different individuals is "the next frontier". Baby steps toward not poisoning people.

RESEARCH

For over a decade, the Tissue Engineering and Biofabrication Lab at ETH Zurich has been trying to grow a human ear. They've finally made one that works (mostly). Published in Advanced Functional Materials, the study describes the first time this group achieved true elastic cartilage rather than the softer fibrocartilage that plagued previous attempts.

The process: take a ~3mm tissue sample from a patient's ear during corrective surgery, expand those cells from about 100,000 to several hundred million, print them into an ear shape, and incubate for roughly 9 weeks. When implanted in rats, the ears maintained their shape and developed mechanical properties similar to natural tissue.

This is for structural reconstruction, not hearing (the ear doesn't restore auditory function). Target patients include children with microtia (congenital ear malformation affecting 1-4 per 10,000 kids) and people who've lost ears to burns or accidents. The current standard involves harvesting rib cartilage, which causes pain, scarring, and produces a stiffer result.

Lead author Philipp Fisch is honest about limitations: the elastin network isn't fully matured yet. "If all goes well, we hope to find the blueprint for the elastin network within the next five years," he said. Clinical use would follow after that. Still, the paper had barely been published before he received a message from the parents of a child with microtia. The need is real.

This week's theme, apparently: making things that actually work. A flu shot that might protect against all flus. A food dye that isn't made from petroleum. Brain tissue that can (briefly) solve physics problems. A tiny chip that catches liver toxicity. An ear that bends as it should.

We're not saying biotech is finally delivering on decades of promises, but... okay, maybe a little bit. Progress is weird and slow and incremental until suddenly it isn't.

Got thoughts on universal vaccines? Opinions on blue M&Ms? Existential concerns about teaching neurons to do engineering? Hit reply, we read everything.

If you enjoyed this, forward it to someone who complains about their flu shot every year.

Keep questioning everything (especially your annual vaccine regimen),

Prateek & Jere

P.S. Somewhere, a blob of mouse neurons just forgot how to balance a pole. Relatable.